Building the case for the calcitonin receptor as a viable target for the treatment of glioblastoma

Researchers are actively seeking novel targeted therapies for the brain tumour glioblastoma (GBM) as the mean survival is less than 15 months. Here we discuss the proposal that the calcitonin receptor (CT Receptor), expressed in 76–86% of patient biopsies, is expressed by both malignant glioma cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Pragya, Furness, Sebastian G. B., Bittencourt, Lucas, Hare, David L., Wookey, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758865/
https://www.ncbi.nlm.nih.gov/pubmed/33425026
http://dx.doi.org/10.1177/1758835920978110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758865/
https://www.ncbi.nlm.nih.gov/pubmed/33425026
http://dx.doi.org/10.1177/1758835920978110

Ejemplares similares